CN108065392A - A kind of composition of assisting in treating hypertension, hyperlipidemic conditions - Google Patents
A kind of composition of assisting in treating hypertension, hyperlipidemic conditions Download PDFInfo
- Publication number
- CN108065392A CN108065392A CN201711270711.0A CN201711270711A CN108065392A CN 108065392 A CN108065392 A CN 108065392A CN 201711270711 A CN201711270711 A CN 201711270711A CN 108065392 A CN108065392 A CN 108065392A
- Authority
- CN
- China
- Prior art keywords
- parts
- astaxanthin
- haematococcus pluvialis
- vitamin
- assisting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 29
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 29
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 29
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 29
- 239000001168 astaxanthin Substances 0.000 claims abstract description 29
- 241000168517 Haematococcus lacustris Species 0.000 claims abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 22
- 239000003921 oil Substances 0.000 claims abstract description 18
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000000605 extraction Methods 0.000 claims abstract description 13
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 13
- 239000011777 magnesium Substances 0.000 claims abstract description 13
- 235000001055 magnesium Nutrition 0.000 claims abstract description 13
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims abstract description 12
- 244000068988 Glycine max Species 0.000 claims abstract description 12
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 12
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 12
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 12
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000010647 garlic oil Substances 0.000 claims abstract description 12
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims abstract description 12
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims abstract description 12
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims abstract description 12
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000005493 rutin Nutrition 0.000 claims abstract description 12
- 229960004555 rutoside Drugs 0.000 claims abstract description 12
- 241000208688 Eucommia Species 0.000 claims abstract description 11
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000003094 microcapsule Substances 0.000 claims abstract description 11
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 11
- 239000011669 selenium Substances 0.000 claims abstract description 11
- 235000011649 selenium Nutrition 0.000 claims abstract description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 10
- 235000004347 Perilla Nutrition 0.000 claims abstract description 10
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 239000007787 solid Substances 0.000 claims abstract description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000009429 Ginkgo biloba extract Substances 0.000 claims abstract description 5
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 5
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 5
- 235000013361 beverage Nutrition 0.000 claims abstract description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940068052 ginkgo biloba extract Drugs 0.000 claims abstract description 5
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 5
- 239000011718 vitamin C Substances 0.000 claims abstract description 5
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 5
- 229940046009 vitamin E Drugs 0.000 claims abstract description 5
- 239000011709 vitamin E Substances 0.000 claims abstract description 5
- 244000124853 Perilla frutescens Species 0.000 claims abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 11
- 229930003231 vitamin Natural products 0.000 claims description 11
- 235000013343 vitamin Nutrition 0.000 claims description 11
- 239000011782 vitamin Substances 0.000 claims description 11
- 229940088594 vitamin Drugs 0.000 claims description 11
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- 229940068065 phytosterols Drugs 0.000 claims description 5
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 3
- 229930182558 Sterol Natural products 0.000 claims description 3
- 150000003432 sterols Chemical class 0.000 claims description 3
- 235000003702 sterols Nutrition 0.000 claims description 3
- 240000007087 Apium graveolens Species 0.000 claims description 2
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims description 2
- 235000010591 Appio Nutrition 0.000 claims description 2
- 208000021267 infertility disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 230000036772 blood pressure Effects 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004204 blood vessel Anatomy 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 5
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 4
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 150000002632 lipids Chemical class 0.000 abstract description 3
- 210000002966 serum Anatomy 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 2
- -1 phytosterol Substances 0.000 abstract description 2
- 239000000470 constituent Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 235000019198 oils Nutrition 0.000 abstract 1
- 230000001151 other effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 241000229722 Perilla <angiosperm> Species 0.000 description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- PFRGXCVKLLPLIP-UHFFFAOYSA-N diallyl disulfide Chemical compound C=CCSSCC=C PFRGXCVKLLPLIP-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 241000168525 Haematococcus Species 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229930184727 ginkgolide Natural products 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000000899 Gutta-Percha Substances 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241001465805 Nymphalidae Species 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 240000000342 Palaquium gutta Species 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical class C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000588 gutta-percha Polymers 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Disclosed by the invention is the composition of a kind of assisting in treating hypertension, hyperlipidemic conditions, is mixed including following components：Water-soluble Astaxanthin In Haematococcus Pluvialis spore powder with crushed sporoderm or Astaxanthin In Haematococcus Pluvialis microcapsule powder or Astaxanthin In Haematococcus Pluvialis oil, dietary fiber, garlic oil, Herba Apii graveolentis extract, Extraction of rutin object, soybean oligopeptide, eucommia leaf extract, perilla herb oil, ginkgo biloba extract, phytosterol, magnesium, selenium, vitamin C, vitamin E, the present invention has prevention of cardiovascular disease, improve blood vessel elasticity, improve blood circulation, blood pressure lowering, serum cholesterol-lowering, reducing blood lipid, strengthen immunity and other effects, formula and preparation process are simple, it can be made into solid beverage, capsule, tablet, constituent is natural, it is substantially without side-effects to human body.
Description
Technical field
The present invention relates to a kind of assisting in treating hypertension, the compositions of hyperlipidemic conditions, belong to field of health care food.
Background technology
Hypertension and hyperlipidemia are the common disease of two kinds of " three high " and middle-aged and elderly people, frequently-occurring disease, many elderlys
In order to prevent and symptom management, can a large amount of take medicine, for the patient for suffering from hypertension, hyperlipidemia, they are main
By drug therapy with reach reduce blood pressure, blood fat purpose, and treat now hypertension, hyperlipidemia drug generally have it is higher
Toxic side effect, be also easy to produce dependence and drug resistance, patient takes lowering blood pressure and blood fat clinical drug adverse reaction and includes at present
A variety of symptoms, mainly include：Flush, headache, palpitating speed, ankle oedema etc., can only control on medication effect
Symptom processed can not fundamentally improve body hypertension, the symptom of hyperlipidemia, and therefore, it is natural to be badly in need of a kind of ingredient, to human body
It is without side-effects, and the non-drug product with prevention of cardiovascular disease, improvement blood vessel elasticity.
The content of the invention
In order to solve above-mentioned prior art problem, the present invention, which provides, has treatment hypertension, hyperlipidemia, have no toxic side effect,
Effect waits well a kind of assisting in treating hypertension, the composition of hyperlipidemic conditions of technical characterstics.
To achieve these goals, the present invention is achieved by the following technical solutions：
A kind of assisting in treating hypertension of the present invention, the composition of hyperlipidemic conditions, are mixed by mass fraction including following components
It closes：20-3000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis spore powder with crushed sporoderm or 10-2000 parts of Astaxanthin In Haematococcus Pluvialis are micro-
Capsule powder or 5-600 portions of Astaxanthin In Haematococcus Pluvialis oil, 50-30000 parts of dietary fibers, 1-1000 portions of garlic oils, 1-800 portions of celeries
Extract, 1-1200 parts of Extraction of rutin objects, 1-1500 parts of soybean oligopeptides, 1-1800 parts of eucommia leaf extracts, 1-1000 parts of purples
Soviet Union's oil, 1-2000 parts of ginkgo biloba extracts, 1-1600 parts of phytosterols, 10-400 parts of magnesium, 0.001-0.18 parts of selenium, 1-200 parts of dimensions
C, 0.1-10 parts of vitamin Es of raw element.
A kind of assisting in treating hypertension of the present invention, the composition of hyperlipidemic conditions, are mixed by mass fraction including following components
It closes：20-1200 parts of water-soluble Astaxanthin In Haematococcus Pluvialis spore powder with crushed sporoderm or 10-400 parts of Astaxanthin In Haematococcus Pluvialis are micro-
Capsule powder, 50-3500 part dietary fiber, 1-200 portions of garlic oils, 1-150 parts of Herba Apii graveolentis extracts, 1-180 parts of Extraction of rutin objects, 1-
130 parts of soybean oligopeptides, 1-200 parts of eucommia leaf extracts, 1-150 parts of perilla herb oils, 1-200 parts of ginkgo biloba extracts, 1-170 parts of plants
Object sterol, 10-400 part magnesium, 0.001-0.18 parts of selenium, 1-100 parts of vitamin Cs, 0.1-10 parts of vitamin Es, 0.2-50 parts of tristearin
Sour magnesium, 1-5 part citric acid, 1-10 parts of food flavors.
As an improvement it can be made into solid beverage, capsule and tablet after the component mixing.
Beneficial effects of the present invention：Can with prevention of cardiovascular disease, improve blood vessel elasticity, improve blood circulation, blood pressure lowering,
Serum cholesterol-lowering, reducing blood lipid, strengthen immunity；Ingredient is natural, without side-effects to human body, suitable for the trouble of all ages and classes level
Person uses；The free radical between human body cell and intracellular free radical can be removed, protects cells from peroxidization
Injury, enables cell normally effectively to carry out metabolism；It can prevent plasma low density lipoprotein from aoxidizing, while can also be notable
Increasing high density lipoprotein and reduction low-density lipoprotein；Can get through blocking blood vessel, resist angina pectoris, prevention myocardial infarction and
Angiocardiopathy；
Dietary fiber can inhibit the absorption of cholesterol, reduce the level of significance that angiocardiopathy occurs；
Herba Apii graveolentis extract main component is the derivative of cumarin and furocoumarin, and there is blood pressure lowering, drop serum courage to consolidate
The effect of alcohol and reducing blood lipid；
Garlic oil main component for Allyl disulfide, diallyl disulphide, Diallytrisin, allicin etc.,
There is anticancer and blood pressure lowering；
Extraction of rutin object main component is a kind of glycocide, plays an important role of that auxiliary reduces blood pressure；
The short chain polypeptides and a small amount of free amino acid that soybean oligopeptide is mainly made of 2-10 amino acid form, and have suppression
The activity of Angiotensin-Converting processed can prevent blood vessel distal from shrinking, so as to have the function that reduce blood pressure；
Eucommia leaf extract main component is cloves resin double glycosides and Gutta-percha glycosides etc., has the physiology work(to reduce blood pressure
Energy；
Perilla herb oil be adjusted blood fat, inhibit thrombus disease (myocardial infarction and cerebral vessels embolism), reduce critical pressure value with
And reduce hypertension harm；
Ginkgo biloba extract main component is Ginkgolides, ginkgolides, Bilobalide, has softening blood vessel, eliminates blood
Fat in liquid reduces cholesterol, improves the effects that blood circulation；
Phytosterol contestable hinders intestinal absorption cholesterol, has the work(for reducing cholesterol and prevention of cardiovascular disease
Energy；
Vitamin E plays an important role of improvement cardiovascular function, it and vitamin C all have oxidation resistant effect.
Specific embodiment
Below by way of specific embodiment, the present invention is further illustrated, but embodiments of the present invention and from
The limitation of following embodiment.
Embodiment 1
The composition of a kind of assisting in treating hypertension, hyperlipidemic conditions is mixed by mass fraction including following components：
20 parts of water-soluble Astaxanthin In Haematococcus Pluvialis spore powder with crushed sporoderm or 10 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders or 5 parts of rain give birth to red ball
Algae astaxanthin oil, 50 parts of dietary fibers, 1 portion of garlic oil, 1 part of Herba Apii graveolentis extract, 1 part of Extraction of rutin object, 1 part of soybean oligopeptide, 1
Part eucommia leaf extract, 1 part of perilla herb oil, 1 part of ginkgo biloba extract, 1 part of phytosterol, 10 parts of magnesium, 0.001 part of selenium, 1 part of vitamin
C, 0.1 part of vitamin E, the component mixing are made predominantly into solid beverage, capsule.
Embodiment 2
The composition of a kind of assisting in treating hypertension, hyperlipidemic conditions is mixed by mass fraction including following components：
1510 parts of water-soluble Astaxanthin In Haematococcus Pluvialis spore powder with crushed sporoderm or 1005 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders or 302 parts of rain
Raw haematococcus astaxanthin oil, 15025 parts of dietary fibers, 500 portions of garlic oils, 400 parts of Herba Apii graveolentis extracts, 600 parts of Extraction of rutin objects,
750 parts of soybean oligopeptides, 900 parts of eucommia leaf extracts, 500 parts of perilla herb oils, 1000 parts of ginkgo biloba extracts, 800 parts of phytosterols,
205 parts of magnesium, 0.09 part of selenium, 100 parts of vitamin Cs, 5 parts of vitamin Es, the component mixing are made predominantly into solid beverage, capsule.
Embodiment 3
The composition of a kind of assisting in treating hypertension, hyperlipidemic conditions is mixed by mass fraction including following components：
3000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis spore powder with crushed sporoderm or 2000 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders or 600 parts of rain
Raw haematococcus astaxanthin oil, 30000 parts of dietary fibers, 1000 portions of garlic oils, 800 parts of Herba Apii graveolentis extracts, 1200 parts of Extraction of rutin
Object, 1500 parts of soybean oligopeptides, 1800 parts of eucommia leaf extracts, 1000 parts of perilla herb oils, 2000 parts of ginkgo biloba extracts, 1600 parts of plants
Object sterol, 400 parts of magnesium, 0.18 part of selenium, 200 parts of vitamin Cs, 10 parts of vitamin Es, the component mixing are made predominantly into solid drink
Material, capsule.
Embodiment 4
The composition of a kind of assisting in treating hypertension, hyperlipidemic conditions is mixed by mass fraction including following components：
20 parts of water-soluble Astaxanthin In Haematococcus Pluvialis spore powder with crushed sporoderm or 10 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders, 50 parts of meals fibres
Dimension, 1 portion of garlic oil, 1 part of Herba Apii graveolentis extract, 1 part of Extraction of rutin object, 1 part of soybean oligopeptide, 1 part of eucommia leaf extract, 1 part of purple
Revive oil, 1 part of ginkgo biloba extract, 1 part of phytosterol, 10 parts of magnesium, 0.001 part of selenium, 1 part of vitamin C, 0.1 part of vitamin E, 0.2 part
Magnesium stearate, 1 part of citric acid, 1 part of food flavor, the component mixing are made predominantly into tablet.
Embodiment 5
The composition of a kind of assisting in treating hypertension, hyperlipidemic conditions is mixed by mass fraction including following components：
610 parts of water-soluble Astaxanthin In Haematococcus Pluvialis spore powder with crushed sporoderm or 205 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders, 1775 portions of meals
Fiber, 100 portions of garlic oils, 75 parts of Herba Apii graveolentis extracts, 90 parts of Extraction of rutin objects, 65 parts of soybean oligopeptides, 100 parts of folium cortex eucommiae extractions
Object, 75 parts of perilla herb oils, 100 parts of ginkgo biloba extracts, 85 parts of phytosterols, 205 parts of magnesium, 0.09 part of selenium, 50 parts of vitamin Cs, 5 parts of dimensions
Raw element E, 25 parts of magnesium stearates, 3 parts of citric acids, 5.5 parts of food flavors, the component mixing are made predominantly into tablet.
Embodiment 6
The composition of a kind of assisting in treating hypertension, hyperlipidemic conditions is mixed by mass fraction including following components：
1200 parts of water-soluble Astaxanthin In Haematococcus Pluvialis spore powder with crushed sporoderm or 400 parts of Astaxanthin In Haematococcus Pluvialis microcapsule powders, 3500 portions of meals
Eat fiber, 200 portions of garlic oils, 150 parts of Herba Apii graveolentis extracts, 180 parts of Extraction of rutin objects, 130 parts of soybean oligopeptides, 200 parts of Cortex Eucommiaes
Leaf extract, 150 parts of perilla herb oils, 200 parts of ginkgo biloba extracts, 170 parts of phytosterols, 400 parts of magnesium, 0.18 part of selenium, 100 parts of dimension lifes
Plain C, 10 parts of vitamin Es, 50 parts of magnesium stearates, 5 parts of citric acids, 10 parts of food flavors, the component mixing are made predominantly into tablet.
Finally it should be noted that the invention is not restricted to above example, there can also be many variations.This field it is general
All deformations that logical technical staff directly can export or associate from present disclosure are considered as the present invention's
Protection domain.
Claims (3)
1. the composition of a kind of assisting in treating hypertension, hyperlipidemic conditions, which is characterized in that include following components by mass fraction
It mixes：20-3000 parts of water-soluble Astaxanthin In Haematococcus Pluvialis spore powder with crushed sporoderm or 10-2000 parts of Astaxanthin In Haematococcus Pluvialis
Microcapsule powder or 5-600 portions of Astaxanthin In Haematococcus Pluvialis oil, 50-30000 parts of dietary fibers, 1-1000 portions of garlic oils, 1-800 portions of celerys
Dish extract, 1-1200 parts of Extraction of rutin objects, 1-1500 parts of soybean oligopeptides, 1-1800 parts of eucommia leaf extracts, 1-1000 parts
Perilla herb oil, 1-2000 part ginkgo biloba extract, 1-1600 parts of phytosterols, 10-400 parts of magnesium, 0.001-0.18 parts of selenium, 1-200 parts
Vitamin C, 0.1-10 part vitamin E.
2. the composition of a kind of assisting in treating hypertension, hyperlipidemic conditions, which is characterized in that include following components by mass fraction
It mixes：20-1200 parts of water-soluble Astaxanthin In Haematococcus Pluvialis spore powder with crushed sporoderm or 10-400 parts of Astaxanthin In Haematococcus Pluvialis
Microcapsule powder, 50-3500 part dietary fiber, 1-200 portions of garlic oils, 1-150 parts of Herba Apii graveolentis extracts, 1-180 parts of Extraction of rutin objects, 1-
130 parts of soybean oligopeptides, 1-200 parts of eucommia leaf extracts, 1-150 parts of perilla herb oils, 1-200 parts of ginkgo biloba extracts, 1-170 parts of plants
Object sterol, 10-400 part magnesium, 0.001-0.18 parts of selenium, 1-100 parts of vitamin Cs, 0.1-10 parts of vitamin Es, 0.2-50 parts of tristearin
Sour magnesium, 1-5 part citric acid, 1-10 parts of food flavors.
3. a kind of infertile Astaxanthin In Haematococcus Pluvialis product formula of auxiliary treatment according to claim 1-2,
It is characterized in that, solid beverage, capsule and tablet is can be made into after the component mixing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711270711.0A CN108065392A (en) | 2017-12-05 | 2017-12-05 | A kind of composition of assisting in treating hypertension, hyperlipidemic conditions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711270711.0A CN108065392A (en) | 2017-12-05 | 2017-12-05 | A kind of composition of assisting in treating hypertension, hyperlipidemic conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108065392A true CN108065392A (en) | 2018-05-25 |
Family
ID=62157849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711270711.0A Pending CN108065392A (en) | 2017-12-05 | 2017-12-05 | A kind of composition of assisting in treating hypertension, hyperlipidemic conditions |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108065392A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109645295A (en) * | 2019-01-17 | 2019-04-19 | 云南龙布瑞生物科技有限公司 | A kind of Astaxanthin In Haematococcus Pluvialis solid beverage maintaining cardiovascular system health |
| CN110946985A (en) * | 2019-09-20 | 2020-04-03 | 安徽优胜康健康科技有限公司 | Ginseng thorn haematococcus pluvialis herbaceous composite solid electuary and preparation method and application thereof |
| CN112425655A (en) * | 2020-11-24 | 2021-03-02 | 吴兆盈 | Formula milk powder for preventing hyperlipidemia, hyperglycemia and hypertension and preparation method thereof |
| CN116076640A (en) * | 2021-11-08 | 2023-05-09 | 莒南和信食品有限公司 | Application and process of beta-sitosterol in beverage |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002825A (en) * | 2007-01-11 | 2007-07-25 | 西北农林科技大学 | Method for preparing Duzhong soft capsule rich in alpha-linolenic acid and effective component of bark of eucommia |
| CN101111239A (en) * | 2004-12-03 | 2008-01-23 | 富士化学工业株式会社 | Composition for body fat reduction |
| CN104126798A (en) * | 2014-07-29 | 2014-11-05 | 溧阳市天目湖保健品有限公司 | Health food capable of regulating blood pressure function and preparation method thereof |
| CN105878801A (en) * | 2016-05-10 | 2016-08-24 | 胡铭 | Red kojic rice astaxanthin composition with blood lipid lowering effect |
-
2017
- 2017-12-05 CN CN201711270711.0A patent/CN108065392A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101111239A (en) * | 2004-12-03 | 2008-01-23 | 富士化学工业株式会社 | Composition for body fat reduction |
| CN101002825A (en) * | 2007-01-11 | 2007-07-25 | 西北农林科技大学 | Method for preparing Duzhong soft capsule rich in alpha-linolenic acid and effective component of bark of eucommia |
| CN104126798A (en) * | 2014-07-29 | 2014-11-05 | 溧阳市天目湖保健品有限公司 | Health food capable of regulating blood pressure function and preparation method thereof |
| CN105878801A (en) * | 2016-05-10 | 2016-08-24 | 胡铭 | Red kojic rice astaxanthin composition with blood lipid lowering effect |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109645295A (en) * | 2019-01-17 | 2019-04-19 | 云南龙布瑞生物科技有限公司 | A kind of Astaxanthin In Haematococcus Pluvialis solid beverage maintaining cardiovascular system health |
| CN110946985A (en) * | 2019-09-20 | 2020-04-03 | 安徽优胜康健康科技有限公司 | Ginseng thorn haematococcus pluvialis herbaceous composite solid electuary and preparation method and application thereof |
| CN112425655A (en) * | 2020-11-24 | 2021-03-02 | 吴兆盈 | Formula milk powder for preventing hyperlipidemia, hyperglycemia and hypertension and preparation method thereof |
| CN116076640A (en) * | 2021-11-08 | 2023-05-09 | 莒南和信食品有限公司 | Application and process of beta-sitosterol in beverage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Naeem et al. | Advancement and future directions towards herbal treatment for various diseases | |
| CN108065392A (en) | A kind of composition of assisting in treating hypertension, hyperlipidemic conditions | |
| JP2021008447A (en) | Health keeping product composition applicable to adult female, elderly, and sub-healthy people | |
| CN107126485A (en) | It is a kind of to aid in improving Chinese medicine composition of sleep and its preparation method and application | |
| KR100529793B1 (en) | The extract of pine needle and the use thereof | |
| CN107006856A (en) | One kind enhancing endurance, raising anti anoxia tolerance nutritional agents and preparation method thereof | |
| CN103566150A (en) | Medicine and food homologous food composition with blood fat reducing function as well as application thereof | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CA2551657A1 (en) | Composition comprising an aqueous extract of red vine leaves and a antithrombotic agent for the treatment of chronic venous insufficiences | |
| EP1520584A1 (en) | Composition for the activation of the immune system | |
| CN104225067B (en) | Chinese medicine composition, preparation method and purposes for treating postmenopausal osteoporosis | |
| KR100204166B1 (en) | Composition for anti-stress | |
| CN105901722A (en) | Euphausia superba oil healthcare capsule for preventing Alzheimer's disease | |
| RU2452507C1 (en) | Phytotranquiliser | |
| KR20010009653A (en) | Composition for treating sexual dysfunction | |
| CN112791150A (en) | Traditional Chinese medicine composition for treating neck vascular plaque and preparation method thereof | |
| KR20020074905A (en) | Constituents for herbal healthy food containing radish extracts | |
| CN106474190A (en) | A kind of medicine for treating type Ⅱdiabetes mellitus and complication and preparation method thereof | |
| Xiang et al. | Scavenging and anti-fatigue activity of Wu-Wei-Zi aqueous extracts | |
| CN1192771C (en) | Medicine for treating rheumatism and rheumatoid disease | |
| Hassan et al. | Phytochemical and Ethnobotanical Effects of Aloe vera | |
| KR20010017629A (en) | Composition of healthfood for stamina-enhancement | |
| CN100488513C (en) | Medicine for treating cerebrovascular and cardiovascular diseases and preparation process thereof | |
| Jain et al. | Hawthorn–Lysine | |
| JP2004196750A (en) | Stress reliever |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180525 |